Pembrolizumab is a monoclonal antibody against the programmed cell death 1 (PD-1) receptor, and is widely used for the treatment of various malignancies,
including melanoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, and Hodgkin's lymphoma. In this study, we evaluated the efficacy and safety of pembrolizumab in patients with advanced or recurrent urothelial carcinoma.

Methods {#Sec2}
=======